No argument there - the cardio risk will be the marketing message of GILD, but eGFR decline will be the marketing message of ViiV. It'll be an interesting fight and I haven't yet placed my bets. I think GILD is overvalued (and apparently, insiders happen to agree).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.